Tscan Therapeutics, Inc. SEC Filings

TScan Therapeutics, Inc. filings document the regulatory record for a clinical-stage biotechnology company developing TCR-engineered T cell therapies. Its 8-K filings furnish operating results, corporate presentations, and pipeline disclosures tied to TSC-101, the ALLOHA heme program, CD45-targeted candidates, solid-tumor research, and autoimmunity target discovery.

The company’s filings also cover governance and capital-structure matters, including officer role changes, compensation and retention arrangements, costs associated with portfolio prioritization, and proxy proposals for director elections, auditor ratification, and authorized common stock. The records identify TCRX voting common stock as listed on the Nasdaq Global Market.